Important New Two Year Milestone Determined for DLBCL Patients

A new study in the Journal of Clinical Oncology has very important implications for patients with diffuse large B-cell lymphoma (DLBCL).

According to Matthew Maurer, assistant professor of biostatistics at the Mayo Clinic and the study's lead author, newly diagnosed patients with DLBCL who experience no cancer-related outcome events (such as disease progression or relapse) for two years following diagnosis can look forward to the same life expectancy as they did before they were diagnosed.

Making the two year mark such an important milestone will change the way patients are counseled by their physicians and likely give hope to many patients who otherwise may have found themselves waiting for as many as five years.

"Patients want to know the good and the bad, and they want to know the natural history of the disease and their long-term risk of dying," said Maurer. "It is extremely useful to be able to assess how their risk of relapse changes as they remain in a disease-free state. If a patient is in event-free remission for two years, we can now say they are more likely to die from something else than from their lymphoma."

In order to reach these surprising conclusions, Mayo researchers followed 767 DLBCL patients enrolled in the Mayo Clinic/University of Iowa Specialized Program of Research Excellence in Lymphoma (SPORE) molecular epidemiology resource database. These patients were treated with rituximab and anthracycline-based chemotherapy.

On review of pathology and medical records, researchers found that as patients remained event-free, their outcomes improved until eventually pulling equal to that of the age- and sex-matched general population at 24 months post-diagnosis.

These results have been confirmed in by another two French studies involving 820 patients.

Source: Mayo Clinic

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap